Daniel Pelletier

9.3k total citations · 1 hit paper
104 papers, 5.8k citations indexed

About

Daniel Pelletier is a scholar working on Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Neurology. According to data from OpenAlex, Daniel Pelletier has authored 104 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Pathology and Forensic Medicine, 27 papers in Radiology, Nuclear Medicine and Imaging and 16 papers in Neurology. Recurrent topics in Daniel Pelletier's work include Multiple Sclerosis Research Studies (69 papers), Advanced MRI Techniques and Applications (12 papers) and RNA regulation and disease (10 papers). Daniel Pelletier is often cited by papers focused on Multiple Sclerosis Research Studies (69 papers), Advanced MRI Techniques and Applications (12 papers) and RNA regulation and disease (10 papers). Daniel Pelletier collaborates with scholars based in United States, Canada and France. Daniel Pelletier's co-authors include Sarah J. Nelson, Andrew W. Bollen, Annette Langer‐Gould, Ari Green, Scott W. Atlas, Darin T. Okuda, Roland G. Henry, David A. Hafler, Radhika Srinivasan and David C. Mohr and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and NeuroImage.

In The Last Decade

Daniel Pelletier

98 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab

2005 761 citations Ari Green, Daniel Pelletier et al. profile →

Peers

Countries citing papers authored by Daniel Pelletier

Since Specialization

Citations

This map shows the geographic impact of Daniel Pelletier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Pelletier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Pelletier more than expected).

Fields of papers citing papers by Daniel Pelletier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Pelletier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Pelletier. The network helps show where Daniel Pelletier may publish in the future.

Co-authorship network of co-authors of Daniel Pelletier

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Pelletier. A scholar is included among the top collaborators of Daniel Pelletier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Pelletier. Daniel Pelletier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The expected loss of feature diversity (versus phylogenetic diversity) following rapid extinction at the present 2023 ·Journal of Mathematical Biology ·(unknown), Daniel Pelletier, Mike Steel	3
2	In vivo cortical glutathione response to oral fumarate therapy in relapsing-remitting multiple sclerosis: A single-arm open-label phase IV trial using 7-Tesla 1H MRS 2023 ·NeuroImage Clinical ·Christoph Juchem, Kelley M. Swanberg, Hetty Prinsen, Daniel Pelletier	2
3	myMS; A Comprehensive Patient-Centered Mobile App to Monitor MS at Home (P3.2-003) 2019 ·Neurology ·Daniel Pelletier, (unknown), (unknown), (unknown), Steven Cen	2
4	An Automated Statistical Technique for Counting Distinct Multiple Sclerosis Lesions 2018 ·American Journal of Neuroradiology ·Jordan D. Dworkin, Kristin A. Linn, İpek Oğuz, Greg Fleishman, Rohit Bakshi, Govind Nair, Peter A. Calabresi, Roland G. Henry, Jiwon Oh, Nico Papinutto, Daniel Pelletier, William D. Rooney, W. Stern, Nancy L. Sicotte, Daniel S. Reich, Russell T. Shinohara	27
5	Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study (S10.002) 2017 ·Neurology ·Douglas L. Arnold, Michael Barnett, Cristoforo Comi, Gavin Giovannoni, Daniel Pelletier, Àlex Rovira, Sven Schippling, Bart Van Wijmeersch, David Margolin, Karthinathan Thangavelu, Anthony Traboulsee	0
6	Anomalies Characteristic of Central Nervous System Demyelination 2017 ·Neurologic Clinics ·Christine Lebrun‐Frénay, Orhun H. Kantarci, Aksel Sıva, Daniel Pelletier, Darin T. Okuda	11
7	Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study (S12.006) 2017 ·Neurology ·Àlex Rovira, Aaron Boster, Giancarlo Comi, Regina Berkovich, Daniel Pelletier, Sven Schippling, Anthony Traboulsee, Christopher LaGanke, David Margolin, Sourav Santra, Douglas L. Arnold	1
8	Multi-center, randomized, double-blinded assessment of teriflunomide in extending the time to a first clinical event in radiologically isolated syndrome (RIS) The TERIS study (P6.359) 2017 ·Neurology ·Christine Lebrun‐Frénay, Aksel Sıva, Orhun H. Kantarci, Christina Azevedo, Maria Pia Sormani, Daniel Pelletier, Darin T. Okuda	7
9	Alemtuzumab Durably Slows Brain Volume Loss Over 6 Years in the Absence of Continuous Treatment in Patients With Active RRMS Who Were Treatment-Naive (CARE-MS I) or Had an Inadequate Response to Prior Therapy (CARE-MS II) (P2.104) 2017 ·Neurology ·Anthony Traboulsee, Michael Barnett, Gıancarlo Comı, Christopher LaGanke, Daniel Pelletier, Àlex Rovira, Sven Schippling, David Margolin, Karthinathan Thangavelu, Kunio Nakamura, Douglas L. Arnold	1
10	Whole-brain atrophy 2016 ·Current Opinion in Neurology ·Christina Azevedo, Daniel Pelletier	27
11	Genetic associations with brain cortical thickness in multiple sclerosis 2015 ·Genes Brain & Behavior ·Takuya Matsushita, Lohith Madireddy, Till Sprenger, Pouya Khankhanian, Stefano Magon, Yvonne Naegelin, Eduardo Caverzasi, Raija L.P. Lindberg, Ludwig Kappos, Stephen L. Hauser, Jorge R. Oksenberg, Roland G. Henry, Daniel Pelletier, Sergio E. Baranzini	23
12	Are individuals with Radiologically Isolated Syndrome have a different clinical outcome once they convert to Clinically Isolated Syndrome? (P5.193) 2015 ·Neurology ·Aksel Sıva, Melih Tütüncü, Orhun H. Kantarci, Uğur Uygunoğlu, Pınar Acar, Aslı Kurne, Mark Keegan, Ayşe Altıntaş, (unknown), Rana Karabudak, Daniel Pelletier, Darin T. Okuda, Christine Lebrun‐Frénay	0
13	A Phase II Trial Of Neuroprotection With Riluzole In Early Relapsing-Remitting MS: Lessons For Future Neuroprotection Trials (P5.017) 2014 ·Neurology ·Emmanuelle Waubant, Amir‐Hadi Maghzi, (unknown), Rebecca Spain, Laura Julián, Ellen M. Mowry, Jacqueline Marcus, Shuang Liu, Ari Green, Charles E. McCulloch, Daniel Pelletier	1
14	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study 2013 ·BMC Neurology ·Tanuja Chitnis, Charles R.G. Guttmann, (unknown), Alexander Musallam, Bianca Weinstock‐Guttman, E. Ann Yeh, Moses Rodriguez, Jayne Ness, Mark Gorman, Brian C. Healy, Nancy L. Kuntz, Dorothée Chabas, Jonathan B. Strober, Emmanuelle Waubant, Lauren Krupp, Daniel Pelletier, Bradley J. Erickson, Niels Bergsland, Robert Zivadinov	5
15	Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis? 2013 ·Psychological Medicine ·Michelle Nicole Burns, (unknown), Mary Kwasny, Daniel Pelletier, David C. Mohr	38
16	Multislice Brain Myelin Water Fractions at 3T in Multiple Sclerosis 2007 ·Journal of Neuroimaging ·Joonmi Oh, Eric Han, Michael Lee, Sarah J. Nelson, Daniel Pelletier	62
17	Corpus Callosum Axonal Injury in Multiple Sclerosis Measured by Proton Magnetic Resonance Spectroscopic Imaging 2004 ·Archives of Neurology ·Joonmi Oh, Daniel Pelletier, Sarah J. Nelson	17
18	Measurement of Whole-Brain Atrophy in Multiple Sclerosis 2004 ·Journal of Neuroimaging ·Daniel Pelletier, Kathleen A. Garrison, Roland G. Henry	65
19	Directional diffusion in relapsing‐remitting multiple sclerosis: A possible in vivo signature of Wallerian degeneration 2003 ·Journal of Magnetic Resonance Imaging ·Roland G. Henry, Joonmi Oh, Sarah J. Nelson, Daniel Pelletier	63
20	Dissociating perceptual and conceptual implicit memory in multiple sclerosis patients 2002 ·Brain and Cognition ·(unknown), Andrew P. Yonelinas, Tracy Luks, David C. Newitt, Joonmi Oh, Ying Lü, Sarah J. Nelson, Donald E. Goodkin, Daniel Pelletier	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact